The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 17, 2026
Filed:
Feb. 01, 2019
Applicant:
The Cleveland Clinic Foundation, Cleveland, OH (US);
Inventors:
Stanley L. Hazen, Pepper Pike, OH (US);
Zeneng Wang, Shaker Heights, OH (US);
Xinmin S. Li, Cleveland, OH (US);
Assignee:
The Cleveland Clinic Foundation, Cleveland, OH (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/198 (2006.01); A61K 31/133 (2006.01); A61K 31/4164 (2006.01); A61K 31/675 (2006.01); A61P 9/04 (2006.01); A61P 13/12 (2006.01); G01N 21/33 (2006.01); G01N 24/08 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/198 (2013.01); A61K 31/133 (2013.01); A61K 31/4164 (2013.01); A61K 31/675 (2013.01); A61P 9/04 (2018.01); A61P 13/12 (2018.01); G01N 21/33 (2013.01); G01N 24/08 (2013.01); A61K 45/06 (2013.01); G01N 2800/34 (2013.01);
Abstract
The present invention relates to systems, kits, and methods for identifying subjects with increased levels of N6-trimethyl-lysine (TML) or the combination of TML and trimethylamine-n-oxide (TMAO), as well as methods of determining risk of disease (e.g., kidney disease or heart failure) based on such levels. In certain embodiments, subjects with elevated TML, or TML and TMAO are treated with a therapeutic (e.g., one that inhibits the TMA/FMO3/TMAO pathway).